Gynecologic Cancer

The National Academy of Medicine announced the election of 90 regular members and 10 international members.

The FDA granted fast track designation to nemvaleukin alfa as part of combination therapy for treatment of platinum-resistant ovarian cancer, according to the agent’s manufacturer.

Although cervical cancer elimination appears to be within reach in the United States, a predictive model anticipated an approximately decade-long gap between low-poverty and high-poverty areas of the country in achieving this goal.

In a study of patients with endometrial stromal sarcomas treated with aromatase inhibitors the objective response rate was more modest than expected, but a majority did achieve stable disease, according to a study presented at the ASCO Annual Meeting.

The FDA approved a combination of pembrolizumab and chemotherapy, with or without bevacizumab, for certain women with persistent, recurrent or metastatic cervical cancer.

Genomic testing has afforded today’s patient the advantage of knowing when they harbor a potentially dangerous genetic mutation, such as BRCA1 or BRCA2.

David A. Eagle, MD, will join New York Cancer & Blood Specialists on Oct. 15.

The FDA granted priority review to cemiplimab-rwlc for treatment of certain women with advanced cervical cancer.

More than a third of patients with solid tumors showed evidence of antitumor response after treatment with ADP-A2M4CD8, according to data presented at the virtual ESMO Congress.

Hispanic adults had lower rates of overall cancer incidence between 2014 and 2018, but higher rates of liver and stomach cancers compared with whites, according to study results published in CA: A Cancer Journal for Clinicians.